UK markets closed
NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,636.22 +82.61 (+0.42%) CRUDE OIL
79.65 -0.41 (-0.51%) GOLD FUTURES
2,430.30 +12.90 (+0.53%) DOW
39,806.77 -196.82 (-0.49%) Bitcoin GBP
54,549.71 +2,565.80 (+4.94%)
Takeda Pharmaceutical Company Limited (4502.T)
Tokyo - Tokyo Delayed price. Currency in JPY
Add to watchlist
At close: 03:15PM JST
| Previous close | 4,130.00 |
| Open | 4,138.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 4,132.00 - 4,174.00 |
| 52-week range | 3,900.00 - 4,873.00 |
| Volume | |
| Avg. volume | 4,284,303 |
| Market cap | 6.535T |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 45.63 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 196.00 (4.75%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- Investor's Business Daily
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.
- Benzinga
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
On Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a restructuring after the company reported a fiscal year 2023 net profit of 144 billion yen (around $954 million), down 54.6% Y/Y. Core net profit fell 12.6% (down 15% at constant currency) to 756.8 billion yen. Takeda said it will incur restructuring costs of about 140 billion yen in fiscal year 2024 as part of a plan to optimize its workforce, cut costs, and strengthen technology. Revenue was 4.26 trillio
- GuruFocus.com
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
Comprehensive Analysis of Q1 2024 Earnings and Strategic Developments
© 2024 Yahoo. All rights reserved.